Comparative efficacy of naltrexone-accelerated versus sublingual buprenorphine in opioid withdrawal management and initiating injectable naltrexone treatment: study protocol for a randomized controlled trial
BackgroundExtended-release injectable naltrexone (XR-NTX), a long-acting opioid antagonist, is an effective relapse prevention strategy in the treatment of opioid use disorder (OUD). However, standard XR-NTX initiation requires completion of opioid withdrawal management and a 1–2 week opioid-free period. This interval is associated with heightened vulnerability to lapse and relapse, and many…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
Belonging Begins in the Body
United States
-
Sex differences in sleep architecture among patients with severe mental disorders: a polysomnographic study
Switzerland
-
A comparison of recovery benefits associated with participation in SMART Recovery, AA, both SMART and AA, or neither, following a new alcohol use disorder recovery attempt
Switzerland
-
Metabolic syndrome in stable long-term antipsychotic monotherapy and polypharmacy among patients with schizophrenia: a real-world comparative study
Switzerland
-
Personality and cognition across the lifespan: investigating their interplay and age-related differences
Switzerland
-
Clinical and resting-state EEG changes following neurofeedback in adult refugees with persistent trauma-related symptoms: a transdiagnostic pre–post observational study
Switzerland
-
Disability and its correlates among older adults with common mental disorders in China: a 5-year follow-up study
Switzerland
-
Referrals for suicidality to a UK child and adolescent mental health service: an evaluation of the policy and practice context of response to suicidal young people
Switzerland